SEARCH

SEARCH BY CITATION

References

  • 1
    Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989; 49: 490612.
  • 2
    Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994; 83: 13907.
  • 3
    Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10: 54851.
  • 4
    Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999; 134: 44550.
  • 5
    Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 192732.
  • 6
    Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 20511.
  • 7
    Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87: 18995.
  • 8
    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002; 116: 4657.
  • 9
    Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29: 29.
  • 10
    Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 4436.
  • 11
    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 7548.
  • 12
    Shan D, Ledbetter JA, Press OW. Apoptosis of maligant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 164452.
  • 13
    Taji H, Kagami Y, Okada Y, Andou M, Nishi Y, Saito H, Seto M, Morishima Y. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998; 89: 74856.
  • 14
    Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000; 204: 5563.
  • 15
    Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000; 60: 71706.
  • 16
    Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26: 13343.
  • 17
    Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001; 97: 13928.
  • 18
    Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G. Binding to CD20 by anti-B1 antibody or F (ab′)2 is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51: 1524.
  • 19
    Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99: 13149.
  • 20
    Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 103843.
  • 21
    Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7: 7117.
  • 22
    Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 1988; 85: 20812.
  • 23
    Stamenkovic I, Seed B. Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein. J Exp Med 1988; 167: 197580.
  • 24
    Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998; 161: 32428.
  • 25
    Oettgen HC, Bayard PJ, Van Ewijk W, Nadler JM, Terhorst CP. Further biochemical studies of the human B-cell antigens B1 and B2. Hybridoma 1983; 2: 1728.
  • 26
    Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121: 112132.
  • 27
    Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quarternary structure. Blood 2002; 99: 325662.
  • 28
    Smeland E, Godal T, Ruud E, Beiske K, Funderud S, Clark EA, Pfeifer-Ohlsson S, Ohlsson R. The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. Proc Natl Acad Sci USA 1985; 82: 62559.
  • 29
    Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985; 135: 3795801.
  • 30
    Clark EA, Shu G, Ledbetter JA. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci USA 1985; 82: 176670.
  • 31
    Golay J, Cusmano G, Introna M. Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. J Immunol 1992; 149: 3008.
  • 32
    Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol 1986; 8: 8817.
  • 33
    Golay JT, Crawford DH. Pathways of human B-lymphocyte activation blocked by B-cell-specific monoclonal antibodies. Immunology 1987; 62: 27984.
  • 34
    Clark EA, Shu G. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J Immunol 1987; 138: 720.
  • 35
    Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule is functionally linked with B cell activation and differentiation. J Immunol 1985; 135: 973.
  • 36
    Kansas GS, Tedder TF. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. J Immunol 1991; 147: 4094102.
  • 37
    Bourget I, Breittmayer JP, Grenier-Brossette N, Cousin JL. CD20 monoclonal antibodies down-regulate IgM at the surface of B cells. Eur J Immunol 1993; 23: 76871.
  • 38
    Bourget I, Di Berardino W, Breittmayer JP, Grenier-Brossette N, Plana-Prades M, Bonnefoy JY, Cousin JL. CD20 monoclonal antibodies stimulate extracellular cleavage of the low affinity receptor for IgE (Fc epsilon RII/CD23) in Epstein-Barr-transformed B cells. J Biol Chem 1994; 269: 692730.
  • 39
    Bourget I, Di Berardino W, Breittmayer JP, Grenier-Brossette N, Plana-Prades M, Bonnefoy JY, Cousin JL. CD20 monoclonal antibodies decrease interleukin-4-stimulated expression of the low-affinity receptor for IgE (Fc epsilon RII/CD23) in human B cells by increasing the extent of its cleavage. Eur J Immunol 1995; 25: 18726.
  • 40
    White MW, McConnell F, Shu GL, Morris DR, Clark EA. Activation of dense human tonsillar B cells. Induction of cy-myc gene expression via two distinct signal transduction pathways. J Immunol 1991; 146: 84653.
  • 41
    Leveille C, AL-DR, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999; 29: 6574.
  • 42
    Holder M, Grafton G, MacDonald I, Finney M, Gordon J. Engagement of CD20 suppresses apoptosis in germinal center B cells. Eur J Immunol 1995; 25: 31604.
  • 43
    Valentine MA, Licciardi KA. Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40. Eur J Immunol 1992; 22: 31418.
  • 44
    Deans JP, Schieven GL, Shu GL, Valentine MA, Gilliland LA, Aruffo A, Clark EA, Ledbetter JA. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. J Immunol 1993; 151: 4494504.
  • 45
    Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 67383.
  • 46
    Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995; 270: 226328.
  • 47
    Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275: 172214.
  • 48
    Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273: 3448.
  • 49
    Field KA, Holowka D, Baird B. Fc epsilon RI-mediated recruitment of p53/56lyn to detergent-resistant membrane domains accompanies cellular signaling. Proc Natl Acad Sci USA 1995; 92: 92015.
  • 50
    Hostager BS, Catlett IM, Bishop GA. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem 2000; 275: 153928.
  • 51
    Brdicka T, Pavlistova D, Leo A et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 2000; 191: 1591604.
  • 52
    Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A, Okada M. Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 2000; 404: 9991003.
  • 53
    Resh MD. Myristylation and palmitylation of Src family members: the fats of the matter. Cell 1994; 76: 4113.
  • 54
    Popoff IJ, Savage JA, Blake J, Johnson P, Deans JP. The association between CD20 and Src-family Tyrosine kinases requires an additional factor. Mol Immunol 1998; 35: 20714.
  • 55
    Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001; 166: 556777.
  • 56
    Martin M, Schneider H, Azouz A, Rudd CE. Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med 2001; 194: 167581.
  • 57
    Tuosto L, Parolini I, Schroder S, Sargiacomo M, Lanzavecchia A, Viola A. Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol 2001; 31: 3459.
  • 58
    Fan JY, Carpentier JL, Van Obberghen E, Grunfeld C, Gorden P, Orci L. Morphological changes of the 3T3-L1 fibroblast plasma membrane upon differentiation to the adipocyte form. J Cell Sci 1983; 61: 21930.
  • 59
    Scherer PE, Lisanti MP, Baldini G, Sargiacomo M, Mastick CC, Lodish HF. Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. J Cell Biol 1994; 127: 123343.
  • 60
    Awasthi-Kalia M, Schnetkamp PP, Deans JP. Differential effects of filipin and methyl-beta-cyclodextrin on B cell receptor signaling. Biochem Biophys Res Commun 2001; 287: 7782.
  • 61
    Kanzaki M, Shibata H, Mogami H, Kojima I. Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 1995; 270: 13099104.
  • 62
    Kanzaki M, Nie L, Shibata H, Kojima I. Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I. J Biol Chemistry 1997; 272: 49649.
  • 63
    Kanzaki M, Lindorfer MA, Garrsion JC, Kojima I. Activation of the calcium-permeable cation channel CD20 by α subunits of the Gi protein. J Biol Chem 1997; 272: 147339.
  • 64
    O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998; 48: 12532.
  • 65
    Ishibashi K, Suzuki M, Sasaki S, Imai M. Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor. Gene 2001; 264: 8793.
  • 66
    Liang Y, Tedder TF. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. Genomics 2001; 72: 11927.
  • 67
    Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 39008.